Citations
All
Search in:AllTitleAbstractAuthor name
Publications
(660)
Patents
Grants
Pathways
Clinical trials
The language you are using is not recognised as English. To correctly search in your language please select Search and translation language
Publication
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
October/1/2018
Abstract
The dedifferentiation, proliferation and migration of vascular smooth muscle cells (VSMCs) are essential in the progression of hypertension, atherosclerosis and intimal hyperplasia. <em>Nesfatin</em>-<em>1</em> is a potential modulator in cardiovascular functions. However, the role of <em>nesfatin</em>-<em>1</em> in VSMC biology has not been explored. The present study was designed to determine the regulatory role of <em>nesfatin</em>-<em>1</em> in VSMC proliferation, migration and intimal hyperplasia after vascular injury. Herein, we demonstrated that <em>nesfatin</em>-<em>1</em> promoted VSMC phenotype switch from a contractile to a synthetic state, stimulated VSMC proliferation and migration in vitro. At the molecular level, <em>nesfatin</em>-<em>1</em> upregulated the protein and mRNA levels, as well as the promoter activities of matrix metalloproteinase 2 (MMP-2) and MMP-9, but downregulated peroxisome proliferator-activated receptor γ (PPARγ) levels and promoter activity in VSMCs. Blockade of MMP-2/9 or activation of PPARγ prevented the <em>nesfatin</em>-<em>1</em>-induced VSMC proliferation and migration. In vivo, knockdown of <em>nesfatin</em>-<em>1</em> ameliorated neointima formation following rat carotid injury. Taken together, our results indicated that <em>nesfatin</em>-<em>1</em> stimulated VSMC proliferation, migration and neointimal hyperplasia by elevating MMP2/MMP-9 levels and inhibiting PPARγ gene expression.
Publication
Journal: European Journal of Applied Physiology
December/9/2010
Abstract
<em>Nesfatin</em>-<em>1</em> is a recently discovered anorectic protein derived from posttranslational processing of the nucleobindin 2 (NUCB2) gene. It is expressed in adipose tissue and is also found in plasma. <em>Nesfatin</em>-<em>1</em> expression is significantly affected by nutritional status and its actions may be involved in the inhibition of the orexigenic effect of ghrelin. Although the effects of physical exercise on several anorectic and orexigenic hormones have been reported, no studies have investigated its effects upon circulating concentrations of <em>nesfatin</em>-<em>1</em>. We investigated the effects of acute strenuous interval exercise and circuit exercise on <em>nesfatin</em> and other hormones affected by metabolic stress. Fourteen provincial and national level young male-kickboxing volunteers participated [age 20.7<em>1</em> ± 2.6 years, height <em>1</em>76.6 ± 2.8 cm, body weight 67.2 ± 3.3 kg, and body mass index (BMI) 2<em>1</em>.56 ± <em>1</em>.42 kg/m(2)]. After an overnight fast, responses to a running-based anaerobic sprint test (RAST; 7 sets of 6 × 35 m every <em>1</em>0 s with <em>1</em> min rest in between sets) and a non-combat kickboxing session (NCKB; 7 sets of 6 techniques, 20 s per technique with <em>1</em> min rest in between sets) were determined. Venous blood samples were collected before, immediately after, and 45 as well as 95 min following the exercises. Plasma GH, insulin, glucose and lactate concentrations significantly increased immediately following the RAST and NCKB protocols, however, plasma <em>nesfatin</em>-<em>1</em> concentrations were not significantly altered. Higher plasma cortisol and glucose concentrations occurred in response to the RAST compared with the NCKB protocols. Although the exercise protocols elicited metabolic stress that significantly altered circulating glucoregulatory hormones, plasma glucose and lactate, there was no significant change in plasma <em>nesfatin</em>-<em>1</em>. A lack of <em>nesfatin</em>-<em>1</em> response to the exercise protocols may be partially due to the fasting condition.
Publication
Journal: Biochemical and Biophysical Research Communications
August/3/2015
Abstract
<em>Nesfatin</em>-<em>1</em> is an 82 amino acid peptide encoded in a secreted precursor, nucleobindin 2. It is an anorexigenic and insulinotropic peptide found abundantly in the hypothalamus, pancreas and gastric oxyntic mucosa. NUCB2 mRNA expression is <em>1</em>0 fold higher in the gastric mucosa than in brain, suggesting gastrointestinal tract as a main source of <em>nesfatin</em>-<em>1</em>. Meal responsive insulin secretion is regulated by incretins glucagon-like peptide-<em>1</em> (GLP-<em>1</em>) and glucose dependent insulinotropic polypeptide (GIP). Since both <em>nesfatin</em>-<em>1</em> and incretins modulate insulin secretion, we hypothesized that <em>nesfatin</em>-<em>1</em> is present in the enteroendocrine cells, and that it regulates incretin secretion. RT-PCR analysis found NUCB2 mRNA expression, and immunofluorescence microscopy determined <em>nesfatin</em>-<em>1</em> immunoreactivity in STC-<em>1</em>, an enteroendocrine cell line. NUCB2/<em>nesfatin</em>-<em>1</em> is co-localized with GLP-<em>1</em> and GIP in mouse small intestinal cells. Static incubation of STC-<em>1</em> cells with <em>nesfatin</em>-<em>1</em> upregulated preproglucagon (GLP-<em>1</em> precursor) mRNA (0.0<em>1</em>, 0.<em>1</em>, <em>1</em> and <em>1</em>0 nM) and GLP-<em>1</em> secretion (0.<em>1</em>, <em>1</em> and <em>1</em>0 nM). <em>Nesfatin</em>-<em>1</em> also enhanced GIP mRNA (0.<em>1</em>, <em>1</em> and <em>1</em>0 nM) and GIP secretion (<em>1</em> and <em>1</em>0 nM). Together, our data support the hypothesis that <em>nesfatin</em>-<em>1</em> is present in enteroendocrine cells and that it stimulates incretin secretion. Future studies should aim for <em>nesfatin</em>-<em>1</em> and incretin interactions in vivo.
Publication
Journal: Current Pharmaceutical Design
July/21/2014
Abstract
<em>Nesfatin</em>-<em>1</em>, derived from an 82-amino-acid peptide precursor protein nucleobindin-2 (NUCB2), is a highly conserved peptide across mammalian species. Initial functional and neuroanatomical studies on NUCB2/<em>nesfatin</em>-<em>1</em> in the central nervous system have supported a role for NUCB2/<em>nesfatin</em>-<em>1</em> as a novel satiety molecule. In recent years, however, it has become apparent that this neuropeptide is involved in various other processes, one of which is the stress response. Stress-associated activation of NUCB2/<em>nesfatin</em>-<em>1</em> neurons, together with <em>nesfatin</em>-<em>1</em>'s central actions in the brain, is indicative of its significance in the stress adaptation response. Interestingly, increasing body of evidence implicates also NUCB2/<em>nesfatin</em>-<em>1</em> in various forms of stress-associated psychopathologies, such as anxiety and depression. In this review, we will outline evidence that has significantly broadened our understanding of the biological significance of NUCB2/<em>nesfatin</em>-<em>1</em> far beyond to be only a hypothalamic peptide with potent anorexigenic actions. NUCB2/<em>nesfatin</em>-<em>1</em> neurons in the brain seem to emerge as novel, integral regulators of the stress adaptation response.
Publication
Journal: Clinical and Experimental Hypertension
September/22/2015
Abstract
We investigated blood <em>nesfatin</em>-<em>1</em> levels in hypertension patients. We found that fasting plasma <em>nesfatin</em>-<em>1</em> levels were significantly higher in hypertension patients than in control groups, especially in overweight/obese hypertension patients (4.5 ± 2.<em>1</em> versus 3.3 ± <em>1</em>.<em>1</em> ng/ml, p < 0.0<em>1</em>). Body mass index, systolic blood pressure and diastolic blood pressure were indeed positively correlated with fasting plasma <em>nesfatin</em>-<em>1</em> levels (r = 0.234, p < 0.05; r = 0.304, p < 0.0<em>1</em>; r = 0.25<em>1</em>, p < 0.05; r = 0.46<em>1</em>, p < 0.0<em>1</em>; respectively). Logistic regression analysis revealed that the plasma level of <em>nesfatin</em>-<em>1</em> could be independent of risk prediction over standard measures (OR = <em>1</em>.547, 95% CI: <em>1</em>.<em>1</em>53-6.273, p = 0.026). <em>Nesfatin</em>-<em>1</em> has the incremental contribution to hypertension risk prediction (IDI: 0.0<em>1</em>4, p = 0.0<em>1</em>8; NRI: 0.050, p = 0.043). The plasma <em>nesfatin</em>-<em>1</em> level in hypertension patients with microalbuminuria are significantly higher than those without microalbuminuria patients (6.4 ± 2.<em>1</em> ng/ml versus 3.9 ± <em>1</em>.8 ng/ml, p < 0.0<em>1</em>). <em>Nesfatin</em>-<em>1</em> might play an important role in obesity hypertension, and its increase could be a risk factor for obesity-associated hypertension.
Publication
Journal: Endocrinology
June/4/2017
Abstract
<em>Nesfatin</em>-<em>1</em>, derived from nucleobindin-2 (NUCB2), is expressed in the hypothalamus, including the paraventricular nucleus (PVN), an integrative center for energy homeostasis. However, precise role of the NUCB2/<em>nesfatin</em>-<em>1</em> in PVN remains less defined. The present study aimed to clarify physiological and/or pathophysiological roles of endogenous NUCB2/<em>nesfatin</em>-<em>1</em> in PVN by using adeno-associated virus vectors encoding short hairpin RNAs targeting NUCB2 in mice. PVN-specific NUCB2 knockdown primarily increased food intake and decreased plasma oxytocin level specifically in light phase, leading to increased body weight gain without affecting energy expenditure. Furthermore, high-salt diet increased the systolic blood pressure, plasma arginine vasopressin (AVP) and AVP mRNA expression in PVN, and all these changes were blunted by PVN-specific NUCB2 knockdown. These results reveal that the endogenous NUCB2/<em>nesfatin</em>-<em>1</em> in PVN regulates PVN AVP and oxytocin and consequently the fluid and energy balance.
Publication
Journal: Molecular Medicine Reports
September/9/2012
Abstract
Obestatin, which is a putative 23-amino-acid peptide, is derived from the C-terminal part of the mammalian preproghrelin gene. <em>Nesfatin</em>-<em>1</em> mRNA is co-expressed with ghrelin in gastric endocrine X/A-like cells; therefore, <em>nesfatin</em>-<em>1</em> may also interact with preproghrelin gene products in the stomach. In this study, we investigated the impact of obestatin on the plasma levels of acyl ghrelin, des-acyl ghrelin and <em>nesfatin</em>-<em>1</em>, and on the gastric emptying of a solid nutrient meal 2 h after an intracerebroventricular (ICV) injection in conscious, fasted rats. The rats were implanted with ICV catheters. Plasma levels of acyl ghrelin, des-acyl ghrelin and <em>nesfatin</em>-<em>1</em>, expected to be co-expressed with obestatin, were measured, whereas the human/rat corticotropin-releasing factor (h/rCRF) was applied as an inhibitor of gastric emptying. The ICV administration of obestatin (0.<em>1</em>, 0.3 and <em>1</em>.0 nmol/rat) did not modify the plasma acyl ghrelin and des-acyl ghrelin levels, the acyl ghrelin/des-acyl ghrelin ratio and <em>nesfatin</em>-<em>1</em> concentrations. The ICV acute administration of obestatin had no influence on the 2-h rate of gastric emptying of a solid nutrient meal, but the ICV h/rCRF injection delayed it. The weight of food ingested <em>1</em> h before ICV injection significantly, but negatively correlated with the gastric emptying of a solid nutrient meal. Our study indicates that the ICV injection of obestatin does not change the 2-h rate of gastric emptying of a solid nutrient meal and the relatively weak interrelationships between ghrelin gene products and <em>nesfatin</em>-<em>1</em>. However, the weight of the ingested food negatively affects the gastric emptying of a solid nutrient meal in conscious, fasted rats.
Publication
Journal: Current Pharmaceutical Design
July/21/2014
Abstract
<em>Nesfatin</em>-<em>1</em>, derived from the precursor NEFA/nucleobindin2 (NUCB2), was initially identified as a feeding-suppressing neuropeptide, acting at central (mainly, hypothalamic) levels in a leptin-independent manner. However, recent experimental evidence strongly suggests that, rather than being a simple anorectic hypothalamic signal, <em>nesfatin</em>-<em>1</em> operates at different tissues as an integral regulator of energy homeostasis and closely related neuroendocrine functions. On the latter, growing, albeit as yet fragmentary, evidence has pointed out recently that NUCB2/ <em>nesfatin</em>-<em>1</em> is involved in the regulation of different aspects of reproductive maturation and function, by acting probably at different levels of the hypothalamic-pituitary-gonadal (HPG) axis. As documented by rodent studies, the reproductive facet of <em>nesfatin</em>-<em>1</em> likely includes (i) a permissive role in (female) pubertal maturation, (ii) stimulatory effects on the gonadotropic axis, whose magnitude, in terms of LH responses, varies depending on the maturational stage and probably the sex and species, and (iii) direct expression and actions in the gonads. These features, together with the proven expression of NUCB2/<em>nesfatin</em>-<em>1</em> in tissues with essential roles in the metabolic control of reproduction, such as the hypothalamus, adipose and pancreas, support a putative role of <em>nesfatin</em>-<em>1</em> as neurohormonal signal linking body metabolic status, puberty and fertility. Curiously enough, although its reproductive dimension seems to be conserved in non-mammalian vertebrates, recent studies in goldfish have surfaced predominant inhibitory actions of <em>nesfatin</em>-<em>1</em> at different levels of the HPG axis in fish. These findings illustrate our as yet limited understanding of this aspect of <em>nesfatin</em>-<em>1</em> physiology, whose relevance in the joint control of metabolism and reproduction in health and disease warrants further investigation.
Publication
Journal: Peptides
January/11/2012
Abstract
Bacterial lipopolysaccharide (LPS) is an established animal model to study the innate immune response to Gram-negative bacteria mimicking symptoms of infection including reduction of food intake. LPS decreases acyl ghrelin associated with decreased concentrations of circulating ghrelin-O-acyltransferase (GOAT) likely contributing to the anorexigenic effect. We also recently described the prominent expression of the novel anorexigenic hormone, nucleobindin2 (NUCB2)/<em>nesfatin</em>-<em>1</em> in gastric X/A-like cells co-localized with ghrelin in different pools of vesicles. To investigate whether LPS would affect gastric and circulating NUCB2/<em>nesfatin</em>-<em>1</em> concentration, ad libitum fed rats were equipped with an intravenous (iv) catheter. LPS was injected intraperitoneally (ip, <em>1</em>00μg/kg) and blood was withdrawn before and at 2, 5, 7 and 24h post injection and processed for NUCB2/<em>nesfatin</em>-<em>1</em> radioimmunoassay. Gastric corpus was collected to measure NUCB2 mRNA expression by RT-qPCR and NUCB2/<em>nesfatin</em>-<em>1</em> protein concentration by Western blot. Injection of LPS increased plasma NUCB2/<em>nesfatin</em>-<em>1</em> concentrations by 43%, 78% and 62% compared to vehicle at 2h, 5h and 7h post injection respectively (p<0.05) and returned to baseline at 24h. The plasma NUCB2/<em>nesfatin</em>-<em>1</em> increase at 2h was associated with increased corpus NUCB2 mRNA expression (p<0.0<em>1</em>), whereas NUCB2 mRNA was not detectable in white blood cells. Likewise, gastric NUCB2 protein concentration was increased by 62% after LPS compared to vehicle (p<0.0<em>1</em>). These data show that gastric NUCB2 production and release are increased in response to LPS. These changes are opposite to those of ghrelin in response to LPS supporting a differential gastric regulation of NUCB2/<em>nesfatin</em>-<em>1</em> and ghrelin expression derived from the same cell by immune challenge.
Publication
Journal: Renal Failure
June/5/2016
Abstract
BACKGROUND
The pathogenetic mechanisms underlying ischemia-reperfusion (I/R) injury involve oxidative stress, inflammation and apoptosis. <em>Nesfatin</em>-<em>1</em>, a novel peptide, has been reported to possess antioxidant, anti-inflammatory and anti-apoptic properties. The study was to examine the potential protective effects of <em>nesfatin</em>-<em>1</em> on renal I/R injury.
METHODS
I/R model was induced by placing a clamp across left renal artery for 45 min followed by 24 h reperfusion, along with a contralateral nephrectom. Twenty-four rats divided into three groups: sham-operated group, vehicle-treated I/R and <em>nesfatin</em>-<em>1</em>-treated I/R. <em>Nesfatin</em>-<em>1</em> was intraperitoneally injected 30 min before renal ischemia. We harvested serum and kidneys at 24 h after reperfusion. Renal function and histological changes were assessed. Marker of oxidative stress and cells in kidney were also evaluated.
RESULTS
The animals with <em>nesfatin</em>-<em>1</em> significantly improved renal functional and histologic lesions induced by I/R injury. The malondialdehyde (MDA) level decreased, whereas superoxide dismutase (SOD) and catalase (CAT) activities were significantly increased. Moreover, <em>nesfatin</em>-<em>1</em>-treated rats had a markedly decrease in apoptotic tubular cells, as well as a decrease in caspase-3 activity and an increase in the bcl-2/Bax ratio.
CONCLUSIONS
This is the first evidence that <em>nesfatin</em>-<em>1</em> treatment ameliorates acute renal I/R injury by suppressing oxidative stress and cell apoptosis. Therefore, it is promising as a potential therapeutic agent for renal IR injury.
Publication
Journal: Psychiatry Investigation
November/12/2018
Abstract
OBJECTIVE
The goal of this study was to evaluate the importance of <em>nesfatin</em>-<em>1</em>, acylated and des-acylated ghrelin, which are known as energy regulatory hormones, in patients with moderate and severe major depression disorders (MDD).
METHODS
Thirty patients with a moderate degree of MDD and, 30 with a severe degree of MDD were used as participants in this study. Thirty subjects without depression were enrolled as a control group. The Hamilton Depression Rating Scale was used to classify the patients with MDD. Blood samples were taken after overnight fasting. The plasma <em>nesfatin</em>-<em>1</em>, acylated ghrelin and des-acylated ghrelin levels were measured using a commercially available enzyme-linked immunosorbent assay kit.
RESULTS
The <em>nesfatin</em>-<em>1</em>, the acylated ghrelin and the des-acylated ghrelin levels were found to be significantly higher in severe MDD (3.92±0.4 ng/mL; 88.56±4.<em>1</em> pg/mL; 962.76±67 pg/mL) as compared to moderate MDD (2.9<em>1</em>±0.5 ng/mL; 77.63±4.<em>1</em>9 pg/mL; 63<em>1</em>.<em>1</em>6±35 pg/mL), or the control (<em>1</em>.0<em>1</em>±0.3 ng/mL; 58.60±9.00 pg/mL; 543.<em>1</em>3±62 pg/mL), respectively.
CONCLUSIONS
Although <em>nesfatin</em>-<em>1</em> and ghrelin are known as adversely affecting the hormones involving the regulation of appetite and food intake, they all increase in depressive patients and are even associated with the severity of the disease. In clinical medicine, the evaluation of the role of <em>nesfatin</em>-<em>1</em> and ghrelin in endocrine and neu-roendocrine regulation of major metabolic functions is an important key mechanism in solving numerous diseases associated with endocrine and neuroendocrine disturbance. Increased levels of <em>nesfatin</em>-<em>1</em> and ghrelin may also be important criteria in describing the prognoses of the patients and the effectiveness of the treatments.
Publication
Journal: Scientific Reports
February/19/2017
Abstract
<em>Nesfatin</em>-<em>1</em> is an 82 amino acid anorexigen encoded in a secreted precursor nucleobindin-2 (NUCB2). NUCB2 was named so due to its high sequence similarity with nucleobindin-<em>1</em> (NUCB<em>1</em>). It was recently reported that NUCB<em>1</em> encodes an insulinotropic <em>nesfatin</em>-<em>1</em>-like peptide (NLP) in mice. Here, we aimed to characterize NLP in fish. RT- qPCR showed NUCB<em>1</em> expression in both central and peripheral tissues. Western blot analysis and/or fluorescence immunohistochemistry determined NUCB<em>1</em>/NLP in the brain, pituitary, testis, ovary and gut of goldfish. NUCB<em>1</em> mRNA expression in goldfish pituitary and gut displayed a daily rhythmic pattern of expression. Pituitary NUCB<em>1</em> mRNA expression was downregulated by estradiol, while testosterone upregulated its expression in female goldfish brain. High carbohydrate and fat suppressed NUCB<em>1</em> mRNA expression in the brain and gut. Intraperitoneal injection of synthetic rat NLP and goldfish NLP at <em>1</em>0 and <em>1</em>00 ng/g body weight doses caused potent inhibition of food intake in goldfish. NLP injection also downregulated the expression of mRNAs encoding orexigens, preproghrelin and orexin-A, and upregulated anorexigen cocaine and amphetamine regulated transcript mRNA in goldfish brain. Collectively, these results provide the first set of results supporting the anorectic action of NLP, and the regulation of tissue specific expression of goldfish NUCB<em>1</em>.
Publication
Journal: Scientific Reports
February/19/2017
Abstract
Several brain-gut peptides have been reported to have a close relationship with the central dopaminergic system; one such brain-gut peptide is <em>nesfatin</em>-<em>1</em>. <em>Nesfatin</em>-<em>1</em> is a satiety peptide that is predominantly secreted by X/A-like endocrine cells in the gastric glands, where ghrelin is also secreted. We previously reported that ghrelin exerted neuroprotective effects on nigral dopaminergic neurons, which implied a role for ghrelin in Parkinson's disease (PD). In the present study, we aim to clarify whether <em>nesfatin</em>-<em>1</em> has similar effects on dopaminergic neurons both in vivo and in vitro. We show that <em>nesfatin</em>-<em>1</em> attenuates the loss of nigral dopaminergic neurons in the <em>1</em>-methyl-4-phenyl-<em>1</em>, 2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD. In addition, <em>nesfatin</em>-<em>1</em> antagonized <em>1</em>-methyl-4-phenylpyridillium ion (MPP+)-induced toxicity by restoring mitochondrial function, inhibiting cytochrome C release and preventing caspase-3 activation in MPP+-treated MES23.5 dopaminergic cells. These neuroprotective effects could be abolished by selective inhibition of C-Raf and the extracellular signal-regulated protein kinase <em>1</em>/2 (ERK<em>1</em>/2). Our data suggest that C-Raf-ERK<em>1</em>/2, which is involved in an anti-apoptotic pathway, is responsible for the neuroprotective effects of <em>nesfatin</em>-<em>1</em> in the context of MPTP-induced toxicity. These results imply that <em>nesfatin</em>-<em>1</em> might have therapeutic potential for PD.
Publication
Journal: Frontiers in Pharmacology
February/3/2020
Abstract
Quercetin is a polyphenol with multiple biological activities, and results of our preliminary study showed that it could shorten the immobility time of mice in the forced swimming test and tail suspending test. The aim of this study was to investigate its effects on the behavioral performance of lipopolysaccharide (LPS)-challenged rats and explore the potential mechanism. The results showed that intragastrical administration of quercetin (40 mg/kg) could improve the bodyweight gain of LPS-challenged rats, increase the saccharin preference index in the saccharin preference test and the novel arm preference index in the Y-maze, and decrease the immobility time in the FST. However, it showed no significant effect on the performance of LPS-challenged rats in the Morris water maze and the plasma concentrations of <em>nesfatin</em>-<em>1</em>, C-reactive protein (CRP), and IL-6. Results of western blot showed that the expression levels of BDNF, Copine 6, p-TrkB, and the triggering receptors expressed on myeloid cells (TREM) <em>1</em> were decreased in both the hippocampus and the prefrontal cortex (PFC) of LPS-challenged rats, while the expression of TREM2 was increased. The protein expression of synapsin-<em>1</em> was decreased in the hippocampus without significant changes in the PFC. These imbalance protein expressions could be balanced by treatment with quercetin. The results suggested that quercetin could alleviate LPS-induced depression-like behaviors and impairment of learning and memory in rats, the mechanism of which might be involved with regulating the BDNF-related imbalance expression of Copine 6 and TREM<em>1</em>/2 in the hippocampus and the PFC.
Publication
Journal: Acta Cardiologica Sinica
November/13/2018
Abstract
UNASSIGNED
<em>Nesfatin</em>-<em>1</em> is a novel anorectic neuropeptide with potent metabolic regulatory effects. It regulates blood pressure, heart rate, cardiomyocyte metabolism and permeability. SYNTAX score, which is an angiographic scoring system, defines the grade and complexity of coronary artery disease (CAD). We aimed to evaluate the relationship between <em>nesfatin</em>-<em>1</em> level and severity of CAD according to the SYNTAX score in patients with non-ST segment elevation myocardial infarction (NSTEMI).
UNASSIGNED
A total of <em>1</em>09 subjects were enrolled into the study, of whom 80 underwent coronary angiography (CA) with the diagnosis of NSTEMI and 29 had normal coronary arteries detected in CA. NSTEMI patients were divided into 2 groups: low SYNTAX score (< 32) (45 patients) and high SYNTAX score (≥ 32) (35 patients).
UNASSIGNED
The NSTEMI patients with a high SYNTAX score (score ≥ 32) had a lower serum <em>nesfatin</em>-<em>1</em> level (62 pg/ml; 39-98) compared to the NSTEMI patients with a low SYNTAX score (score < 32) (<em>1</em>38 pg/ml; 65-286) and the control group (392 pg/ml; <em>1</em>78-<em>1</em>320). There was also a negative correlation between serum <em>nesfatin</em>-<em>1</em> level and SYNTAX score (r = -0.594, p < 0.00<em>1</em>). A lower serum level of <em>nesfatin</em>-<em>1</em> (odds ratio = 0.<em>1</em><em>1</em>6; 95% confidence interval: 0.<em>1</em>38- 0.094; p < 0.00<em>1</em>) was an independent predictor for high SYNTAX score in the NSTEMI patients after multiple linear regression analysis.
UNASSIGNED
Serum <em>nesfatin</em>-<em>1</em> level was lower in the high SYNTAX group than in the low SYNTAX group in patients with NSTEMI. <em>Nesfatin</em>-<em>1</em>could have a role in the pathogenesis of atherosclerotic burden in patients with NSTEMI.
Publication
Journal: Comparative biochemistry and physiology. Part A, Molecular & integrative physiology
November/10/2016
Abstract
The macronutrient composition of diets is a very important factor in the regulation of body weight and metabolism. Several lines of research in mammals have shown that macronutrients differentially regulate metabolic hormones, including ghrelin and <em>nesfatin</em>-<em>1</em> that have opposing effects on energy balance. This study aimed to determine whether macronutrients modulate the expression of ghrelin and the nucleobindin-2 (NUCB2) encoded <em>nesfatin</em>-<em>1</em> in goldfish (Carassius auratus). Fish were fed once daily on control, high-carbohydrate, high-protein, high-fat and very high-fat diets for 7 (short-term) or 28 (long-term) days. The expression of preproghrelin, ghrelin O-acyl transferase (goat), growth hormone secretagogue receptor <em>1</em> (ghs-r<em>1</em>) and nucb2/<em>nesfatin</em>-<em>1</em> mRNAs was quantified in the hypothalamus, pituitary, gut and liver. Short-term feeding with fat-enriched diets significantly increased nucb2 mRNA levels in hypothalamus and liver, preproghrelin, goat and ghs-r<em>1</em> expression in pituitary, and ghs-r<em>1</em> expression in gut. Fish fed on a high-protein diet exhibited a significant reduction in preproghrelin and ghs-r<em>1</em> mRNAs in the liver. After long-term feeding, fish fed on high-carbohydrate and very high-fat diets had significantly increased preproghrelin, goat and ghs-r<em>1</em> expression in pituitary. Feeding on a high-carbohydrate diet also upregulated goat and ghs-r<em>1</em> transcripts in gut, while feeding on a high-fat diet elicited the same effect only for ghs-r<em>1</em> in liver. Nucb2 expression increased in pituitary, while it decreased in gut after long-term feeding of a high-protein diet. Collectively, these results show for the first time in fish that macronutrients differentially regulate the expression of ghrelinergic and NUCB2/<em>nesfatin</em>-<em>1</em> systems in central and peripheral tissues of goldfish.
Publication
Journal: Lipids in Health and Disease
January/18/2019
Abstract
<AbstractText>Previous studies have shown that physical training and natural diet able to change the expression and concentration of peptides and proteins. Myokines and adipokines play an important role in metabolism and metabolic syndrome. Therefore, the purpose of the present study was to investigate the effect of high-intensity interval training (HIIT) and supplementation of flaxseed oil on plasma irisin, <em>nesfatin</em>-<em>1</em> and resistin in male rats.</AbstractText><AbstractText>Forty adult male rats were randomly divided into four groups (ten in each group) including Control-Saline (CS), Training-Saline (TS), Control-FlaxOil supplement (CO), and Training-FlaxOil supplement (TO). The training groups performed for <em>1</em>0 weeks and 5 sessions each week, interval training with 90-95% VO2max on rodent treadmill, and supplement groups received flaxseed oil (300 mg / kg). Five days after the last training session, rats were sacrificed. Blood samples were taken from the heart and plasma was evaluated.</AbstractText><AbstractText>Exercise Training significantly increased plasma levels of irisin (P = 0.0<em>1</em>9), <em>nesfatin</em>-<em>1</em> (P = 0.0<em>1</em>), and decreased resistin (P = 0.0<em>1</em>). Flaxseed oil significantly reduced plasma resistin levels (P = 0.02). Plasma irisin levels in the supplementation group were higher than all groups (P = 0.04<em>1</em>).</AbstractText><AbstractText>There was a significant positive correlation between plasma levels of irisin with <em>nesfatin</em>-<em>1</em> and negative correlation with resistin. HIIT program with flaxseed oil as a modality can create a metabolic crosstalk between skeletal muscle and adipose tissues and have health benefits.</AbstractText>
Publication
Journal: Neuropeptides
March/3/2016
Abstract
Among numerous side effects of antipsychotic drugs (neuroleptics), one of the leading problems is a significant weight gain caused by disturbances in energy homeostasis. The hypothalamus is considered an important target for neuroleptics and contains some neuronal circuits responsible for food intake regulation, so we decided to study which hypothalamic signaling pathways connected with energy balance control are modified by antipsychotic drugs of different generations. We created an expression profile of different neuropeptides after single-dose and chronic neuroleptic administration. Experiments were carried out on adult male Sprague-Dawley rats injected intraperitoneally for <em>1</em> day or for 28 days by three neuroleptics: olanzapine, chlorpromazine and haloperidol. Hypothalami were isolated in order to perform PCR reactions and also whole brains were sliced for immunohistochemical analysis. We assessed the expression of orexigenic/anorexigenic neuropeptides and their receptors--neuropeptide Y (NPY), NPY receptor type <em>1</em> (Y<em>1</em>R), preproorexin (PPOX), orexin A, orexin receptor type <em>1</em> (OX<em>1</em>R) and 2 (OX2R), nucleobindin 2 (NUCB2), <em>nesfatin</em>-<em>1</em>, proopiomelanocortin (POMC), alpha-melanotropin (α-MSH) and melanocortin receptor type 4 (MC4R)--both on the mRNA and protein levels. We have shown that antipsychotics of different generations administered chronically have the ability to upregulate PPOX, orexin A and Y<em>1</em>R expression with little or no effect on orexigenic receptors (OX<em>1</em>R, OX2R) and NPY. Interestingly, antipsychotics also increased the level of some anorexigenic factors (POMC, α-MSH and MC4R), but at the same time strongly downregulated NUCB2 and <em>nesfatin</em>-<em>1</em> signaling--a newly discovered neuropeptide known as a food-intake inhibiting factor. Our results may contribute to a better understanding of mechanisms responsible for antipsychotics' side effects. They also underline the complex nature of interactions between classical monoamine receptors and hypothalamic peptidergic pathways, which has potential clinical applications.
Publication
Journal: Peptides
December/12/2016
Abstract
Hyperglycemia is one of the major causes of suppressed angiogenesis and impaired wound healing leading to chronic wounds. <em>Nesfatin</em>-<em>1</em> a novel peptide was reported to have antioxidant and anti-apoptotic properties. This study is aimed to investigate the potential healing-promoting effects of <em>nesfatin</em>-<em>1</em> in non-diabetic or diabetic rats with surgical wounds. In male Sprague-Dawley rats, hyperglycemia was induced by intraperitoneal (ip) injection of streptozotocin (55 mg/kg). Under anesthesia, dorsum skin tissues of normoglycemic (n=<em>1</em>6) and hyperglycemic rats were excised (2 × 2 cm, full-thickness), while control rats (n=<em>1</em>6) had neither hyperglycemia nor wounds. Half of the rats in each group were treated ip with saline, while the others were treated with <em>nesfatin</em>-<em>1</em> (2 μg/kg/day) for 3 days until they were decapitated. Plasma interleukin-<em>1</em>-beta (IL-<em>1</em>β), transforming growth factor-beta (TGF-β-<em>1</em>), IL-6 levels, and dermal tissue malondialdehyde (MDA), glutathione (GSH) levels, myeloperoxidase (MPO) and caspase-3 activity were measured. For histological examination, paraffin sections were stained with hematoxylin-eosin or Masson's trichrome and immunohistochemistry for vascular endothelial growth factor (VEGF) was applied. ANOVA and Student's t-tests were used for statistical analysis. Compared to control rats, skin MPO activity, MDA and caspase-3 levels were increased similarly in saline-treated normo- and hyperglycemic rats. <em>Nesfatin</em>-<em>1</em> depressed MDA, caspase-3, MPO activity and IL-<em>1</em>β with concomitant elevations in dermal GSH and plasma TGF-β-<em>1</em> levels. Histopathological examination revealed regeneration of epidermis, regular arrangement of collagen fibers in the dermis and a decrease in VEGF immunoreactivity in the epidermal keratinocytes of <em>nesfatin</em>-<em>1</em>-treated groups. <em>Nesfatin</em>-<em>1</em> improved surgical wound healing in both normo- and hyperglycemic rats via the suppression of neutrophil recruitment, apoptosis and VEGF activation.
Publication
Journal: Bosnian Journal of Basic Medical Sciences
June/6/2016
Abstract
Obesity, insulin resistance (IR), inflammation, and hyperandrogenism may lead to polycystic ovary syndrome (PCOS) and hypertension. <em>Nesfatin</em>-<em>1</em> (N<em>1</em>) may be related to IR, obesity, and hypertension. Furthermore, a vitamin D (VD) deficiency is associated with hypertension and PCOS. We aimed to investigate N<em>1</em> and VD levels in PCOS that have an effect on systolic and diastolic blood pressure (BP) and heart rate (HR).This study included 54 patients with PCOS and 48 age-body mass index (BMI)-matched healthy controls. PCOS was diagnosed according to clinical practice guidelines. Ferriman-Gallwey scores (FGS) were calculated, while N<em>1</em>, VD, and other hormonal and biochemical parameters were measured for all subjects. Systolic and diastolic BP was measured as well. HR was calculated using an electrocardiogram.The levels of N<em>1</em> (p < 0.00<em>1</em>), high-sensitivity C-reactive protein (hs-CRP) (p = 0.036), homeostasis model assessment as an index of insulin resistance (HOMA-IR) (p < 0.00<em>1</em>), systolic (p < 0.00<em>1</em>) and diastolic (p < 0.00<em>1</em>) BP and HR (p < 0.00<em>1</em>) in the PCOS group were significantly higher than in the control group. However, the VD levels of the PCOS group were lower than the control group (p = 0.004). N<em>1</em> had a strong positive correlation with BMI, HOMA-IR, hs-CRP, luteinizing hormone, systolic and diastolic BP, and HR. VD levels were negatively correlated with HOMA-IR and luteinizing hormone.Elevated N<em>1</em> and decreased VD levels may be related to the presence of high-normal BP or hypertension in PCOS subjects. N<em>1</em> level may be associated with an increased BP due to its relation to inflammation and IR.
Publication
Journal: Cytokine
July/22/2013
Abstract
OBJECTIVE
To investigate possible alterations in cord blood levels of adipokine <em>nesfatin</em>-<em>1</em> (secreted by adipose tissue and pancreatic β-cells and implicated in glucose metabolism and insulin resistance), as well as insulin, in large (LGA) and appropriate for gestational age (AGA) pregnancies, granted that these groups differ in body fat mass and metabolic/endocrine mechanisms.
METHODS
Cord blood <em>nesfatin</em>-<em>1</em> and insulin concentrations were prospectively measured in 40 LGA (9 born from diabetic and 3<em>1</em> from non-diabetic mothers) and 20 AGA singleton full-term infants as well as their mothers.
RESULTS
Cord blood <em>nesfatin</em>-<em>1</em> concentrations were significantly lower in LGA compared to AGA neonates (b=-0.206, SE 0.07, p=0.005). However, cord blood <em>nesfatin</em>-<em>1</em> concentrations were elevated in infants born from mothers with gestational diabetes mellitus (GDM), compared to those born from non-diabetic mothers, after controlling for group (b=0.<em>1</em>90, SE 0.<em>1</em>0, p=0.05). Finally, cord blood <em>nesfatin</em>-<em>1</em> concentrations were lower in cases of vaginal delivery (b=0.<em>1</em><em>1</em>, SE 0.05, p=0.042). Insulin levels were significantly elevated, as customized centiles increased (b=0.004, SE=0.002, p=0.0<em>1</em>6). No significant correlation was found between insulin and <em>nesfatin</em>-<em>1</em> in maternal and umbilical cord levels.
CONCLUSIONS
In this study <em>nesfatin</em>-<em>1</em> levels are decreased in LGA compared to AGA fetuses. Fetal <em>nesfatin</em>-<em>1</em> concentrations are higher in cases of GDM and cord blood <em>nesfatin</em>-<em>1</em> concentrations are lower in cases of vaginal delivery.
Publication
Journal: Peptides
September/4/2016
Abstract
<em>Nesfatin</em>-<em>1</em> was first shown to be involved in the control of appetite and energy metabolism in the hypothalamus. Many recent reports have shown <em>nesfatin</em>-<em>1</em> expression in various tissues including the pituitary gland, but its expression and regulation mechanisms in the pituitary gland are unclear. Therefore, first, we investigated the mRNA and protein expression of <em>nesfatin</em>-<em>1</em> in the pituitary using qRT-PCR and Western blotting, respectively. Expression of NUCB2 mRNA and <em>nesfatin</em>-<em>1</em> protein was higher in the pituitary gland than in other organs, and <em>nesfatin</em>-<em>1</em> protein was localized in many cells in the anterior pituitary gland. Next, we investigated whether NUCB2 mRNA expression in the pituitary gland was regulated by sex steroid hormones secreted by the ovary. Mice were ovariectomized and injected with progesterone (P4) and <em>1</em>7β-estradiol (E2). The expression of NUCB2 in the pituitary gland was dramatically decreased after ovariectomy and increased with injection of P4 and E2, respectively. The in vitro experiment to elucidate the direct effect of P4 and E2 on NUCB2 mRNA expression showed NUCB2 mRNA expression was significantly increased with E2 and decreased with P4 alone and P4 plus E2 in cultured pituitary tissue. The present study demonstrated that <em>nesfatin</em>-<em>1</em>/NUCB2 was highly expressed in the mouse pituitary and was regulated by P4 and E2. These data suggest that reproductive-endocrine regulation through hypothalamus-pituitary-ovary axis may contribute to <em>nesfatin</em>-<em>1</em>/NUCB2 expression in the pituitary gland.
Publication
Journal: Physiology and Behavior
February/18/2015
Abstract
<em>Nesfatin</em>-<em>1</em> is an anorexigenic neuropeptide derived by post-translational cleavage from the N-terminus region DNA binding/EF-hand/acidic amino acid rich region (NEFA)/nucleobindin2 (NucB2) protein through proteolytic prohormone convertases. This neuropeptide was originally localized in different appetite controlling areas such as the hypothalamic paraventricular nucleus, arcuate nucleus, supraoptic nucleus, lateral hypothalamic area, and nucleus tractus solitarius. The objective of this study was to determine the expression and the changes that occur to mRNA and protein of NucB2 and <em>Nesfatin</em>-<em>1</em> serum levels during gestation. This study utilized molecular and immunological approaches to investigate the expression and regulation of NucB2/<em>Nesfatin</em>-<em>1</em> protein throughout gestation in rat fed under ad libitum and food restricted conditions (30% nutrient restriction). NucB2 was immunolocalized in the amnion and decidua of the rat placenta. <em>Nesfatin</em>-<em>1</em> serum levels were measured by radioimmunoassay on gestational days <em>1</em>2, <em>1</em>6, <em>1</em>9 and 2<em>1</em>, showing a significant (p<0.0<em>1</em>) decrease in serum levels after day <em>1</em>2 until the end of gestation in rats fed ad libitum. These results were correlated with the analysis of NucB2 mRNA, with a significant (p<0.0<em>1</em>) reduction observed in both the mRNA and protein of NucB2 during the gestational days <em>1</em>2, <em>1</em>6 and 2<em>1</em>. It was also observed that food restriction decreases <em>Nesfatin</em>-<em>1</em> serum levels and NucB2 placental expression at day <em>1</em>6 of gestation when compared to pregnant rats fed ad libitum. This study illustrates for the first time through molecular and immunological approaches the NucB2 expression and regulation on rat placenta and that this peptide is regulated throughout pregnancy. Consistent with previous reports, our results provide additional evidence supporting the role of NucB2 protein as an anorexigenic peptide that may contribute to the regulation of feeding behavior and energy homeostasis. NucB2/<em>Nesfatin</em>-<em>1</em> might play an important metabolic role during pregnancy and fetal development and its energy balance mediating role should be studied in various physiological and pathological conditions throughout gestation.
Publication
Journal: Archives of endocrinology and metabolism
November/21/2017
Abstract
OBJECTIVE
To investigate serum <em>nesfatin</em>-<em>1</em> levels at 24-28 weeks of pregnancy in women newly diagnosed with gestational diabetes and determine the association of <em>nesfatin</em>-<em>1</em> with several metabolic parameters.
METHODS
Forty women newly diagnosed with gestational diabetes at 24-28 weeks of pregnancy and 30 healthy pregnant women matched in age and gestational week were included in this cross-sectional study. Serum <em>nesfatin</em>-<em>1</em> levels were analyzed using ELISA, and the relationship between <em>nesfatin</em>-<em>1</em> and several metabolic parameters were assessed.
RESULTS
Serum <em>nesfatin</em>-<em>1</em> levels were found to be lower in women with gestational diabetes compared to the pregnant women in the control sample (p = 0.020). Multiple linear regression analysis revealed that <em>nesfatin</em>-<em>1</em> was lower in participants with gestational diabetes independently from gestational age, BMI, HOMA-IR, fasting plasma glucose, and age. In correlation analysis, the only variable that was found to have a statistically significant correlation with <em>nesfatin</em>-<em>1</em> was gestational age (p = 0.0<em>1</em>5, r = 0.30).
CONCLUSIONS
Lower <em>nesfatin</em>-<em>1</em> levels in women with gestational diabetes compared to the control group at 24-28 weeks of gestation draws attention to <em>nesfatin</em>-<em>1</em> levels in gestational diabetes and motivates further research in this area.
load more...